Raied Abdullah, MD
Nephrology · Gary, INNPI 1063417657
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 208 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$699
- Amgen$638
- Vifor Pharma, Inc.$402
- Otsuka America Pharmaceutical, Inc.$361
- Travere Therapeutics, Inc.$290
- OPKO Pharmaceuticals, LLC$271
- plus $2K from 16 others
Across 106 payments — averaging $1059.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$109K
- Janssen Research & Development, LLC$2K
- Ironwood Pharmaceuticals, Inc$750
What the payments were for
- Food & beverage$4,25999%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $699 |
| Amgen(2 entities) | 35 | $638 |
| Vifor Pharma, Inc. | 21 | $402 |
| Otsuka America Pharmaceutical, Inc. | 21 | $361 |
| Travere Therapeutics, Inc. | 20 | $290 |
| OPKO Pharmaceuticals, LLC | 13 | $271 |
| Novartis | 3 | $268 |
| Ardelyx, Inc. | 6 | $215 |
| Fresenius USA Marketing, Inc. | 12 | $209 |
| Bayer | 12 | $201 |
| ANI Pharmaceuticals, Inc. | 4 | $193 |
| Scpharmaceuticals Inc. | 3 | $103 |
| EKOS Corporation | 1 | $93 |
| Merck | 6 | $89 |
| Calliditas Therapeutics US Inc. | 4 | $65 |
| Novo Nordisk | 3 | $51 |
| GSK | 3 | $46 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$250
- Parsabiv$125
- PURIFIED CORTROPHIN GEL$125
- XPHOZAH 30 MG$120
How this compares
$4,289 in reported general payments places this provider in the 80th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SamscaTolvaptan | 12 | $54,026 |
| VelphoroSucroferric Oxyhydroxide | 12 | $47,661 |
| FarxigaDapagliflozin Propanediol | 25 | $35,859 |
| OzempicSemaglutide | 31 | $30,365 |
| EliquisApixaban | 27 | $26,271 |
| EntrestoSacubitril/Valsartan | 25 | $22,699 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $18,296 |
| Sevelamer Carbonate | 48 | $9,405 |
| Midodrine Hcl | 26 | $3,731 |
| Potassium Chloride | 102 | $2,181 |
| Klor-Con-EfPotassium Bicarbonate/Cit Ac | 15 | $1,575 |
| Metoprolol Succinate | 121 | $1,065 |
| Cinacalcet Hcl | 20 | $870 |
| Hydralazine Hcl | 58 | $720 |
| Bumetanide | 16 | $697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc.Samsca | $18 | $54,02612 claims |
| Fresenius USA Marketing, Inc.Velphoro | $209 | $47,66112 claims |
| AstraZenecaFarxiga | $699 | $35,85925 claims |
| Novo NordiskOzempic | $51 | $30,36531 claims |
| NovartisEntresto | $268 | $22,69925 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $193 | $28117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 238 nephrology providers in Indiana.
Other nephrology in Gary
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Narothama Reddy AeddulaEvansville$125K
- Gaurav VermaTerre Haute$125K
- Manish GeraTerre Haute$113K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Jorge DiegoShelbyville$81K
- Muhammad MujtabaIndianapolis$71K
- Andrew OshaughnessyFort Wayne$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.